Phase 2 Parkinson Clinical Trials
67 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 67 trials
Recruiting
Phase 2
A Trial to Test the Use of Dapansutrile, an Anti-inflammatory Medication, in People With Parkinson's Disease
Parkinson Disease
Cambridge University Hospitals NHS Foundation Trust36 enrolled1 locationNCT07157735
Recruiting
Phase 2Phase 3
A Study of Buntanetap in Participants With PD
Deep Brain StimulationParkinson's Disease (PD)
Annovis Bio Inc.500 enrolled27 locationsNCT07284784
Recruiting
Phase 2
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
Parkinson DiseaseParkinsonParkinson Disease, Idiopathic+2 more
Neuron23 Inc.150 enrolled70 locationsNCT06680830
Recruiting
Phase 2
D-SPARK: A Clinical Trial of D-Serine for Modifying Parkinson's Disease Progression
Parkinson's DiseaseParkinson Disease (PD)
Haukeland University Hospital100 enrolled11 locationsNCT07312110
Recruiting
Phase 2
Psilocybin Therapy for Depression in Parkinson's Disease
DepressionParkinson Disease
Joshua Woolley, MD, PhD60 enrolled1 locationNCT06455293
Recruiting
Phase 2
Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease
Parkinson Disease
Gateway Institute for Brain Research56 enrolled3 locationsNCT05266417
Recruiting
Phase 1Phase 2
This Clinical Trial is Designed to Evaluate the Safety, Tolerability, Feasibility and Preliminary Efficacy of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in Patients With Parkinson's Disease.
Parkinson Disease
iRegene Therapeutics Co., Ltd.5 enrolled1 locationNCT07102342
Recruiting
Phase 2
Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease
Parkinson Disease
Hillhurst Biopharmaceuticals, Inc.36 enrolled1 locationNCT07005180
Recruiting
Phase 2
Probiotic Treatment for Depression and Associated Mood Disorders in Parkinson's Disease
DepressionParkinson DiseasePARKINSON DISEASE (Disorder)
University of British Columbia60 enrolled1 locationNCT05568498
Recruiting
Phase 2
Psilocybin Therapy for Psychological Distress in Palliative Patients
COPD, Chronic Obstructive Pulmonary DiseaseMajor Depressive Disorder (MDD)ALS (Amyotrophic Lateral Sclerosis)+2 more
University Medical Center Groningen108 enrolled4 locationsNCT06782724
Recruiting
Phase 1Phase 2
The University of Alabama at Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy
Parkinson Disease
University of Alabama at Birmingham205 enrolled1 locationNCT03457493
Recruiting
Phase 1Phase 2
rTMS to Improve Cognition in Parkinson's
Mild Cognitive ImpairmentParkinson's Disease
VA Office of Research and Development56 enrolled2 locationsNCT03836950
Recruiting
Phase 2
Ketamine for Veterans With Parkinson's Disease
Parkinson's Disease
VA Office of Research and Development80 enrolled1 locationNCT06231563
Recruiting
Phase 2
A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations
Parkinson Disease
Appello Pharmaceuticals, Inc.150 enrolled25 locationsNCT07432958
Recruiting
Phase 2
Etoricoxib in Patients With Parkinsonian Disease
Parkinson Disease
Ihab Elsayed Hassan60 enrolled1 locationNCT07370532
Recruiting
Phase 2
A Phase 2 Study to Assess the Effects of SUL-238 on High Energy Phosphates With ³¹P-MRS in Patients With Early, Untreated Parkinson's Disease
Parkinson's Disease (PD)
GEN İlaç ve Sağlık Ürünleri A.Ş.45 enrolled1 locationNCT07322887
Recruiting
Phase 2
18F-mFBG Cardiac Uptake With Lewy Body Dementia
Lewy Body Dementia (LBD)Parkinson Disease (PD)
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)20 enrolled1 locationNCT07176286
Recruiting
Phase 2
Reducing Falls With Varenicline in Hypocholinergic Parkinson Disease
Parkinson Disease
Vikas Kotagal102 enrolled1 locationNCT06679374
Recruiting
Phase 2
Safety, Tolerability and Symptomatic Efficacy of the ROCK-Inhibitor Fasudil in Patients With Parkinson's Disease
Idiopathic Parkinson´s Disease
Technical University of Munich75 enrolled1 locationNCT05931575
Recruiting
Phase 2Phase 3
Montelukast in Parkinson Disease
Parkinson Disease
Mostafa Bahaa60 enrolled1 locationNCT06113640